Vor Biopharma (VOR) Total Liabilities (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Total Liabilities data on file, last reported at $657.2 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 1419.71% year-over-year to $657.2 million in Q1 2026; TTM through Mar 2026 was $657.2 million, a 1419.71% increase from a year earlier, with the FY2025 full-year figure at $628.4 million, up 1259.46% from the prior year.
• Total Liabilities for Q1 2026 stood at $657.2 million, up from $628.4 million in the prior quarter.
• Over the last five years, Total Liabilities for VOR reached as high as $2.4 billion in Q3 2025 and fell as low as $39.8 million in Q1 2022.
• Historically, Total Liabilities has averaged $352.6 million across 5 years, with a median of $47.4 million in 2023.
• Across the five-year window, Total Liabilities fell 10.79% in 2024 and soared 5480.73% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $48.8 million in 2022, then decreased by 2.78% to $47.4 million in 2023, then decreased by 2.48% to $46.2 million in 2024, then surged by 1259.46% to $628.4 million in 2025, then grew by 4.57% to $657.2 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $657.2 million in Q1 2026, $628.4 million in Q4 2025, and $2.4 billion in Q3 2025.